Lisata Therapeutics: Imbed Biosciences Launches SAM™ PainGuard™ for Enhanced Wound Care Management
- Imbed Biosciences launches SAM™ PainGuard™ with Lidocaine, enhancing wound care and pain management.
- The PainGuard™ matrix delivers rapid pain relief and antimicrobial protection for various wound types.
- Strong medical community support highlights PainGuard™'s effectiveness and commitment to improving patient outcomes.
Imbed Biosciences Unveils Innovative Pain Management Solution for Wound Care
Imbed Biosciences Inc. announces the launch of its SAM™ PainGuard™ with Lidocaine, marking a significant advancement in the field of wound care. This product introduces two key brands: Surgaflex™ PainGuard™ designed for surgical wounds and Pelashield™ PainGuard™ tailored for burn and trauma management. The SAM™ Antimicrobial Technology platform is a groundbreaking approach that integrates multiple wound care agents into a single bioresorbable polymer matrix. This novel formulation not only provides essential antimicrobial protection but also delivers acute pain relief, addressing a critical need in patient care.
The prevalence of pain post-surgery is a pressing concern in healthcare, with nearly 90% of patients experiencing moderate to severe discomfort following surgical procedures. Imbed’s CEO, Terry Bromley, emphasizes the importance of effective pain management in reducing opioid reliance and preventing complications such as anxiety and delayed recovery. The PainGuard™ matrix is engineered to ensure rapid relief, featuring a controlled release of lidocaine HCl that mimics a 4% ointment, releasing over 80% of the medication within the first 30 minutes. This rapid onset of action makes it particularly suitable for various wound types, including surgical, burn, donor site, trauma, and chronic wounds, enhancing patient comfort during critical periods such as post-excision and dressing changes.
Pre-launch evaluations have demonstrated strong support from the medical community, with physicians highlighting the product's effectiveness in managing pain and its user-friendly application. Testimonials from healthcare providers reveal significant patient benefits, including one instance where a patient ceased hydrocodone use immediately after surgery. The PainGuard™ matrix's combination of antimicrobial silver with lidocaine in a low-toxicity formulation offers sustained protection from microbes for up to 72 hours, mitigating concerns associated with animal-derived ingredients. This innovative approach not only strengthens Imbed Biosciences' portfolio but also underscores its dedication to improving patient outcomes through cutting-edge wound care solutions.
In addition to the launch of the PainGuard™, Imbed Biosciences reinforces its position in the market by addressing key issues in wound management, particularly the need for effective pain relief strategies. The integration of advanced technology in their products highlights the company’s commitment to meeting evolving healthcare demands. This development aligns with broader trends in the healthcare industry, where there is an increasing push for alternatives to traditional pain management methods.
As Imbed Biosciences continues to innovate within the advanced wound care sector, the SAM™ PainGuard™ with Lidocaine stands out as a promising solution that not only enhances patient comfort but also contributes to better overall recovery outcomes.